Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Published in: memo - Magazine of European Medical Oncology 1/2020

Open Access 01-03-2020 | Lymphoma | short review

CAR T-cell therapy in diffuse large B-cell lymphoma

Authors: PD Dr. Georg Hopfinger, Univ. Prof. Dr. Nina Worel

Published in: memo - Magazine of European Medical Oncology | Issue 1/2020

Login to get access

Summary

Diffuse large B‑cell lymphoma (DLBCL) comprises 30–40% of non-Hodgkin’s lymphoma. Clinical factors such as a high International Prognostic Index (IPI) or molecular factors as cell of origin (COO) have an influence on the clinical outcome after conventional immunochemotherapy. Patients with resistant or relapsed (r/r) DLBCL have a poor prognosis with a median overall survival of 6,3 months and low complete response rates (CR 7%) to salvage chemoimmunotherapy. Currently, therapy with autologous chimeric antigen receptor T‑cells (CAR T‑cells) provide encouraging complete responses (CR) of up to 50%. However, high costs for approved products and elaborate logistics have to be encountered.
Literature
1.
Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116(12):2040–5.CrossRef
2.
Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B‑cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184–90.CrossRef
3.
Wohlfarth P, Worel N, Hopfinger G. Chimeric antigen receptor Tcell therapy—a hematological success story. memo. 2018;11(2):116–21.CrossRef
4.
Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B‑cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 2019;20(1):31–42.CrossRef
5.
Jacobson CA, Hunter B, Armand P, et al. Axicabtagene ciloleucel in the real world: outcomes and predictors of response, resistance and toxicity. Blood. 2018;132(Suppl 1):92.CrossRef
6.
Nastoupil LJ, Jain MD, Spiegel JY, et al. Axicabtagene Ciloleucel (Axi-cel) CD19 chimeric antigen receptor (CAR) T‑cell therapy for relapsed/refractory large B‑cell Lymphoma: real world experience. Blood. 2018;132(Suppl 1):91.CrossRef
7.
Jacobson CA, Locke FL, Miklos DB, et al. End of phase 1 results from Zuma-6: Axicabtagene ciloleucel (Axi-Cel) in combination with atezolizumab for the treatment of patients with refractory diffuse large B cell Lymphoma. Blood. 2018;132(Suppl 1):4192.CrossRef
8.
Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B‑cell lymphoma. N Engl J Med. 2019;380(1):45–56.CrossRef
9.
Pasquini M, Hu Z‑H, Zhang Y, et al. Real world experience of tisagenlecleucel chimeric antigen receptor (CAR) T‑cells targeting CD19 in patients with acute lymphoblastic leukemia (ALL) and diffuse large B‑cell lymphoma (DLBCL) using the center for international blood and marrow transplant research (CIBMTR) cellular therapy (CT) registry. Clin Lymphoma Myeloma Leuk. 2019;19:S267.CrossRef
10.
Abramson JS, Gordon LI, Palomba ML, Lunning MA, Arnason JE, Forero-Torres A. Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL. J Clin Oncol. 2018;36:abstr 7505.CrossRef
11.
Abramson J, Palomba M, Arnason J, et al. Lisocabtagene maraleucel (liso-cel) treatment of patients (pts) with relapsed/refractory (R/R) B‑cell non-Hodgkin lymphoma (NHL) and secondary CNS lymphoma: Initial results from TRANSCEND NHL 001. J Clin Oncol. 2019;37(suppl):abstr 7515–2019.
12.
Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T‑cell therapy—assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47–62.CrossRef
13.
Di Blasi R, Aguinaga L, Paillassa J, et al. Infectious complications in patients receiving anti-CD-19 chimeric antigen receptors T‑cells (CAR-T) for diffuse large cell B‑cell lymphoma (DLBCL). A monocentric preliminary experience. S1641. HemaSphere. 2019;3:759.
14.
Topp M, van Meerten T, Wermke M, et al. Axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory large b cell lymphoma: preliminary results of earlier steroid use. PS1067. HemaSphere. 2019;3:483.
15.
Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625–38.CrossRef
16.
Gust J, Hay KA, Hanafi LA, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR‑T cells. Cancer Discov. 2017;7(12):1404–19.CrossRef
17.
Van Den Neste E, Schmitz N, Mounier N, et al. Outcomes of diffuse large B‑cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. Bone Marrow Transplant. 2017;52(2):216–21.CrossRef
18.
Orlando EJ, Han X, Tribouley C, et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med. 2018;24(10):1504–6.CrossRef
19.
Cherkassky L, Morello A, Villena-Vargas J, et al. Human CAR T cells with cell-intrinsic PD‑1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016;126(8):3130–44.CrossRef
20.
Fry TJ, Shah NN, Orentas RJ, et al. CD22-targeted CAR T cells induce remission in B‑ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24(1):20–8.CrossRef
21.
Ormhoj M, Scarfo I, Cabral ML, et al. Chimeric antigen receptor T cells targeting CD79b show efficacy in lymphoma with or without co-targeting CD19. Clin Cancer Res. 2019;25(23):7046–57.CrossRef
22.
Ramos CA, Ballard B, Zhang H, et al. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest. 2017;127(9):3462–71.CrossRef
Metadata
Title
CAR T-cell therapy in diffuse large B-cell lymphoma
Authors
PD Dr. Georg Hopfinger
Univ. Prof. Dr. Nina Worel
Publication date
01-03-2020
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 1/2020
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-019-00558-z

Other articles of this Issue 1/2020

memo - Magazine of European Medical Oncology 1/2020 Go to the issue

original report

Epidemiology of polycythemia vera in a Mexican population

short review

AML—is it time to drive a CAR(-T)?

short review

Palliative sedation for delirium management at the end of life

short review

The top ten things that must be known about end of life therapy in patients with advanced cancer

editorial

The golden anniversary of the Austrian Society of Hematology and Medical Oncology (OeGHO)

short review

Importance of avoiding late cancer-directed therapy in terminally ill cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits